Literature DB >> 15721011

Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine.

Mira Rosenblat1, Jacob Vaya, Diana Shih, Michael Aviram.   

Abstract

We investigated the role of HDL-associated paraoxonase 1 (PON1) in HDL-mediated macrophage cholesterol efflux by using HDL derived from wild type mice (Control-HDL), from human PON1-transgenic mice (HDL-PON1Tg) or from PON1-knockout mice (HDL-PON1(0)). Cholesterol efflux from mouse peritoneal macrophages (MPM) or from J774 A.1 macrophage cell line by HDL-PON1Tg, was significantly increased (by 60%) compared to HDL-PON1(0). We demonstrated that this PON1 effect was associated with an increased HDL binding to the cells, as the binding of HDL-PON1Tg (or HDL-PON1(0) that was enriched with PON1) was increased by 50% compared to that of HDL-PON1(0). Using either a cAMP analogue, to increase ABCA1 receptor expression, or rabbit anti-mouse SR-BI specific antibody to block the SR-BI receptor, PON1 stimulation of HDL binding and of HDL-mediated macrophage cholesterol efflux, were both found to involve the ABCA1 transporter. Studies with PON1 specific inhibitors revealed that PON1 activity was required for its stimulation of HDL-mediated macrophage cholesterol efflux. Upon incubation of macrophages with Control-HDL or with HDL-PON1Tg, macrophage lysophosphatidylcholine (LPC) content was increased by 3.7- and 7.5-fold, respectively. Such an LPC enrichment of macrophages resulted in up to 60% increased HDL binding to the cells, and a 41% increased HDL-mediated cholesterol efflux. Similarly, macrophage loading with LPC (by either adding LPC, or PON1 or phospholipase A(2)) significantly increased apolipoprotein A-I (apoA-I) mediated cholesterol efflux by 104, 65 and 56%, respectively, in ABCA1 overexpressing macrophages. We conclude that HDL-associated PON1 may contribute to the attenuation of atherosclerosis development by its ability to act on macrophage phospholipids, to form LPC, in turn, stimulates HDL binding and HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15721011     DOI: 10.1016/j.atherosclerosis.2004.10.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  41 in total

Review 1.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

2.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

3.  Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults.

Authors:  Ju-Yi Hsieh; Chiz-Tzung Chang; Max T Huang; Chia-Ming Chang; Chia-Ying Chen; Ming-Yi Shen; Hsin-Yi Liao; Guei-Jane Wang; Chu-Huang Chen; Chao-Jung Chen; Chao-Yuh Yang
Journal:  Anal Chem       Date:  2013-11-13       Impact factor: 6.986

4.  Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.

Authors:  Tina Costacou; Andrew P Levy; Rachel G Miller; Janet Snell-Bergeon; Rabea Asleh; Dan Farbstein; Catherine E Fickley; Georgia Pambianco; Rona de la Vega; Rhobert W Evans; Trevor J Orchard
Journal:  Acta Diabetol       Date:  2015-05-24       Impact factor: 4.280

5.  Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound.

Authors:  Cheon Ho Park; Su Duy Nguyen; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2006-04       Impact factor: 1.880

6.  ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport.

Authors:  Kai Yin; Duan-fang Liao; Chao-ke Tang
Journal:  Mol Med       Date:  2010-05-12       Impact factor: 6.354

7.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

8.  Is alcohol beneficial or harmful for cardioprotection?

Authors:  Raj Lakshman; Mamatha Garige; Maokai Gong; Leslie Leckey; Ravi Varatharajalu; Samir Zakhari
Journal:  Genes Nutr       Date:  2010-06       Impact factor: 5.523

9.  A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity.

Authors:  Tiffany L Graves; John E Scott
Journal:  Curr Chem Genomics       Date:  2008-11-26

10.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.